Impact of Immune Checkpoint Inhibitor Therapy on Asthma Exacerbations: A Nationwide Retrospective Cohort Analysis

Overview of attention for article published in The Journal of Allergy and Clinical Immunology, February 2026

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news: 6 news outlets

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 6 news stories from 6 outlets.

ICI Monotherapy Linked to Fewer Asthma Exacerbations

Physician's Weekly, 09 Apr 2026

Patients with cancer receiving immune checkpoint inhibitor (ICI) therapy—specifically pembrolizumab or nivolumab—showed a…

Immune Checkpoint Inhibitor Therapy May Reduce Asthma Exacerbations

Weekly Voice, 16 Feb 2026

Patients receiving pembrolizumab or nivolumab exhibited a modest reduction in asthma exacerbation rates at 24 months -…

Immune Checkpoint Inhibitor Therapy May Reduce Asthma Exacerbations

Yahoo! Finance USA, 16 Feb 2026

Patients receiving pembrolizumab or nivolumab exhibited a modest reduction in asthma exacerbation rates at 24 months MILWAUKEE…

Immune Checkpoint Inhibitor Therapy May Reduce Asthma Exacerbations

Le Lézard, 16 Feb 2026

Classified in: Health Subject: SVY Patients receiving pembrolizumab or nivolumab exhibited a modest reduction in asthma…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.